Pediatric Chronic Anemia

Back

Practice Essentials

Chronic anemia has no precise definition. Anemia that persists for 6 months or more (eg, hereditary spherocytosis [HS]) is clearly chronic; however, anemia that lasts only 2 months (eg, iron deficiency that is being treated) should also be considered chronic anemia, and the reasons for it must be sought.

In contrast to chronic anemia, which develops over months or years, acute anemia develops suddenly, in a matter of hours or days. Acute anemia is usually due to acute blood loss or acute hemolysis. Because the life span of normal erythrocytes is about 120 days, bone marrow failure as the cause of anemia always results in chronic, slow-developing anemia. An exception is acute anemia that occurs in patients with existing chronic anemia. For example, patients with sickle cell anemia who already have chronic anemia may develop additional acute anemia due to bone marrow failure (aplastic crisis). (See the Medscape Drugs & Diseases articles Anemia and Anemia of Prematurity for complete information on these topics.)

Chronic anemia can be primary or secondary.

Primary chronic anemia

Primary chronic anemias are the true chronic anemias, in which anemia (defined as a hemoglobin [Hb] level more than two standard deviations below the mean reference value for age) is part of the basic disease process. The basic disease process is hematologic (eg, sickle cell disease, HS, bone marrow failure), and the degree of anemia varies markedly from etiology to etiology as well as from patient to patient (even in persons with the same etiology). All congenital anemia belongs to this group, whether present at birth or later in childhood. (See Etiology and Workup.)

Secondary chronic anemia

Secondary chronic anemias are chronic anemias that may provide a diagnostic clue to an underlying pathology. They are a consequence of a nonhematologic problem (eg, chronic blood loss, chronic renal failure, osteomyelitis, inflammatory bowel disease, autoimmune disease, tuberculosis). (See Etiology.)

For example, a retrospective study by Aljomah et al found that in pediatric patients with inflammatory bowel disease, 67.31% had anemia at diagnosis, with 38.46% having anemia of chronic disease by itself and 28.85% having iron deficiency anemia alone or suffering from both iron deficiency anemia and anemia of chronic disease.[1]

Complications

Complications that pose a threat to long-term health are often a function of the primary condition that is causing secondary anemia. (See Prognosis and History.)

Complications associated with chronic anemia include the following:

It should be noted that so-called aplastic crisis, mentioned above, may occur in any patients with chronic hemolytic anemia and is characterized by a sudden drop in hemoglobin levels with reticulocytopenia. Patients who are usually well compensated for anemia may develop heart failure due to the sudden drop in hemoglobin. In most cases, patients require blood transfusion. The cause is commonly parvovirus B19 infection and cessation of erythropoiesis. As the patients develop antibodies to the virus, they spontaneously recover. Detection of parvovirus DNA by polymerase–chain reaction (PCR) assay or demonstration of parvovirus B19 immunoglobulin M (IgM) antibodies is diagnostic. The term aplastic crisis is actually a misnomer, because leukopenia and thrombocytopenia are not observed.

Signs and symptoms of pediatric chronic anemia

The following points should be taken into consideration:

Workup in pediatric chronic anemia

Laboratory tests include the following:

Imaging studies include the following:

Bone marrow aspiration and biopsy can be used to rule out leukemia, aplastic anemia, tumor cells in the marrow (such as neuroblastoma), hemosiderosis, megaloblastosis, marrow dysplasia, and hemophagocytosis.

Management of pediatric chronic anemia

Management strategies include the following:

Dietary iron deficiency anemia can be prevented by starting supplemental iron when infants are weaned off breast milk or regular formula at age 6-8 months; 1-2 mg/kg/d of elemental iron is usually sufficient to prevent iron deficiency anemia. This should be continued until the child more or less eats regular table foods as the main source of calories. Treatment of iron deficiency anemia needs a higher dose of iron, usually 6 mg/kg/d of elemental iron, for at least 3 months.

Etiology

As with acute anemia, chronic anemia is classified into the following primary categories:

Decreased red cell production

Marrow aplasia may involve a single cell line, as in Diamond-Blackfan anemia (ie, a pure red cell aplasia), or it may involve all cell lines, as in aplastic anemia.

Acquired aplastic anemia is seen at any age in an otherwise healthy patient.

Transient erythroblastopenia of childhood (TEC) is the most common form of childhood pure red cell aplasia. The peak age range for TEC is 6 months to 6 years. It is usually triggered by a viral illness. In most cases, specific viruses have not been identified,[5] although human herpesvirus type 6[6] and parvovirus B19[7] have been thought to be the cause in some instances. Spontaneous recovery is the rule, but recovery is sometimes prolonged, necessitating blood transfusion. Typically, the reticulocyte count is zero. Unlike Diamond-Blackfan anemia, mean corpuscular volume (MCV) in TEC is not elevated and the anemia is normocytic and normochromic.

Nutritional anemia can take the form of the following:

A growing number of hereditary anemias caused by genetic mutations have been described, with the list including the following:

With regard to the last item, a group of rare congenital, hypochromic, microcytic anemias that do not respond to iron therapy has been described, including the following:

Marrow replacement may involve tumor cells, fibrous tissue, or granulomas. Malignancies that metastasize to bone marrow, resulting in anemia, include neuroblastoma, Hodgkin disease, non-Hodgkin lymphoma (although extensive involvement of the marrow results in a change of definition to leukemia), rhabdomyosarcoma, and primary bone tumors.

Leukemia is the most common malignancy in childhood and may present with just anemia. In infants and young children, neuroblastoma must be considered. Chronic myelocytic leukemia, although rare, may also present as a chronic anemia.

Myelofibrosis with myeloid metaplasia may manifest as fibrous tissue invading the marrow in an uncontrolled fashion; this is one of the conditions within the myeloproliferative spectrum of premalignancies.

Granulomas may occur with any of the TORCH (ie, toxoplasmosis, other infections, rubella, cytomegalovirus infection, herpes simplex) infections in neonates or in patients of any age with miliary tuberculosis.

Impaired erythropoietin production occurs in the anemia of renal failure and may be a partial explanation for anemia of chronic disease.

Hemoglobinopathies of the underproduction type include heterozygous thalassemia syndromes. Normal hemoglobin is underproduced because of mutations affecting production of α-globin or β-globin chains.

Long-term maintenance chemotherapy can cause suppression of DNA synthesis.

Increased red cell destruction (hemolysis)

Extracorpuscular causes of hemolysis include (1) mechanical injury to red blood cells (eg, hemolytic-uremic syndrome [HUS], thrombotic thrombocytopenic purpura [TTP], chronic disseminated intravascular coagulopathy [DIC], giant hemangioma [Kasabach-Merritt phenomenon], hereditary hemorrhagic telangiectasia,[18] cardiac valve defects [usually prosthetic],[19] thermal burns); (2) antibodies (chronic autoimmune hemolysis [warm or cold]);[20] (3) infections, drugs, and toxins; and (4) hypersplenism (secondary to splenomegaly of any cause).

Intrinsic causes of hemolysis include (1) red cell membrane defects (HS, elliptocytosis, stomatocytosis, acanthocytosis, paroxysmal nocturnal hemoglobinuria), (2) red cell enzyme abnormalities (glucose-6-phosphate dehydrogenase [G-6-PD] deficiency, pyruvate kinase deficiency, glutathione synthetase deficiency), (3) hemoglobinopathies (homozygotes of hemoglobins S, C, D, E or the thalassemias or double heterozygotes of the above and unstable hemoglobin, such as Hb Köln, Hb Nottingham, and Hb Zürich).

Anemia due to decreased red cell production and increased hemolysis

This includes the following:

Anemia due to blood loss

The following may cause anemia:

Epidemiology

The overall prevalence of chronic anemia varies with ethnic group, geographic location, sex, age, and other factors. Worldwide, undiagnosed iron deficiency is probably the most common cause of isolated chronic anemia, especially in children aged 1-5 years and in teenagers. This may reflect inadequate nutritional iron and/or the effects of chronic parasitic infestations (eg, hookworm). (Anemia is also seen in persons with generalized malnutrition states but not as an isolated finding.)

In Mediterranean and Middle Eastern populations, β-thalassemia trait is an important consideration in the differential diagnosis of chronic anemia at any age; α-thalassemia is seen more commonly in Southeast Asia, India, and the Middle East.

Chronic anemia is a major public health problem in developing and underdeveloped nations, with the prevalence being much higher than in developed countries. It is most often due to nutritional deficiency, including iron deficiency, and compounded by parasitic infestations, malaria, human immunodeficiency virus (HIV) disease, and other infections.

Nonetheless, according to a report by Stevens et al, while 48% of children worldwide aged 6-59 months had anemia in 2000, by 2019 this figure had fallen to 40%. The investigators stated that about 25-50% of children in this age group and women aged 15-49 years, with anemia, have iron deficiency; however, in populations in which the burden of anemia and infections is high, the proportion of anemia related to iron deficiency may be lower.[21]

The treatment and prevention of chronic anemia require a global endeavor to raise general nutritional status and eliminate common infections. An additional important factor is hemoglobinopathies prevalent in malaria-infested areas.

The increasing population migration from the endemic areas of hemoglobinopathies to Northern European and North American countries has created new diagnostic and management problems for those countries that have not previously experienced this type of challenge.[22, 23] The endemic areas of hemoglobinopathies are Mediterranean countries, Asian Indian countries, Southeast Asian countries, and sub-Saharan African countries.[23] The hemoglobinopathies with significant frequencies in these regions are α- and β-thalassemia, sickle cell anemia, hemoglobin C and hemoglobin E diseases, and combinations of these hemoglobinopathies.[24] Patients with these hemoglobinopathies present with chronic anemia.

Race-related demographics

Certain racial groups are much more likely than others to have inherited anemias. Hemoglobin S syndromes are usually (although not invariably) seen in populations of central African origin; hemoglobin C syndromes are seen in populations of western African origin. Hemoglobin D syndromes are usually seen in populations of northern India, and hemoglobin E syndromes are seen in populations of Southeast Asia. β-thalassemias are seen in Mediterranean, Middle Eastern, Southeast Asian, African, and Indian populations, while α-thalassemias are seen in African, Middle Eastern, and Asian populations.

Chronic anemia due to G-6-PD deficiency is more likely in individuals of Mediterranean, Middle Eastern, or Southeast Asian origin. However, Black males have a high prevalence of G-6-PD deficiency that causes a hemolytic episode (an acute hemolytic episode, not chronic anemia) upon exposure to a strong oxidant, such as moth balls.

Sex-related demographics

Males are much more likely to have G-6-PD deficiency than are females, although chronic anemia due to this enzyme deficiency in Blacks is rare.

Immune hemolytic anemias are more common in adolescent females because of the higher prevalence of autoimmune diseases.

Chronic iron deficiency or chronic iron deficiency anemia is relatively common in menstruating teenagers.

Age-related demographics

The most common pediatric anemia is dietary iron deficiency anemia. It is most prevalent from age 6 months to 2 years. Onset of Diamond-Blackfan anemia is usually in early infancy. Transient erythroblastopenia of childhood (TEC) typically affects patients aged 6 months to 6 years.

Onset of homozygous or doubly heterozygous hemoglobinopathies (β-chain mutations such as sickle cell disease, hemoglobin E disease, β-thalassemia trait) occurs in later infancy, while α-chain mutation (α-thalassemia, hemoglobin H disease) manifests shortly after birth.

The toddler years are the period of lead poisoning; such exposure to lead may result in anemia owing to impaired heme synthesis, red cell hemolysis, and shortened survival of red cells.

Onset of menses leads to susceptibility to iron deficiency.

Prognosis

The prognosis is a function of the underlying cause of secondary anemia. Generally, the prognosis in patients with stable chronic anemia is good.

Death resulting from chronic anemia is extremely uncommon because of the adaptive ability of the cardiovascular system.

Morbidity is also uncommon and is usually related to the primary disease process rather than to the anemia per se. Shortness of breath and easy fatigability are unpredictable because some children tolerate extremely low hemoglobin concentrations, in the range of 4-5 g/dL, without any problem, whereas other children are symptomatic with values at 2 times that concentration. No evidence suggests that such low hemoglobin concentrations pose any systemic problems, but low concentrations can be distressing to children and families.

There is a remarkable paucity of data regarding what hemoglobin level is good enough for a patient with chronic anemia to maintain a normal growth rate. Although patients with β-thalassemia major are known to have growth failure, the confounding factor of iron overload and endocrinopathy prevents a straightforward interpretation of the relationship between hemoglobin level and growth.

In situations of true red blood cell (RBC) aplasia, the anemia eventually reaches a point at which compensatory mechanisms are no longer adequate, and congestive heart failure or syncope can result.

Patient Education

Keep mothballs and naphthalene out of all children’s reach, in case they have G-6-PD deficiency.

Avoid strenuous activities, particularly contact sports, if a child has splenomegaly, to avoid rupture.

Teach parents to palpate the spleen in patients with sickle cell disease to detect splenic sequestration.

Remember to give folic acid daily to children with chronic hemolytic anemia.

Educate parents regarding the possibility of aplastic crisis in children with sickle cell disease and HS (sudden pallor, lethargy, anorexia).

α-Thalassemia trait is most commonly confused with iron deficiency anemia. It would be helpful to write the diagnosis on a paper and give it to parents so that their children will not be given iron therapy unnecessarily by other physicians.

Provide appropriate genetic counseling to patients with hereditary forms of anemia.

Advise parents regarding the risks of blood transfusion.

Parents should also be made aware that in children older than 8 months, nourishment through breastfeeding alone results in iron deficiency and iron deficiency anemia.

Blue sclerae occur in several conditions, including iron deficiency, and thus when caregivers notice them, iron should be checked.

History

Patients with chronic anemia are usually asymptomatic, even with remarkably low levels of hemoglobin.

Symptoms more often relate to the underlying cause; for example, irritability, pagophagia (ice eating), and lethargy can occur if the anemia is secondary to iron deficiency; paresthesia of hands and feet, if the anemia is due to vitamin B12 deficiency; left upper quadrant pain, if the anemia is the result of HS and splenomegaly; intolerance to fatty foods, if the anemia is caused by chronic hemolysis with subsequent cholelithiasis; and constipation and cold intolerance, if the anemia is the result of hypothyroidism. Undetected celiac disease or renal failure sometimes manifest as chronic anemia and failure to thrive. Diarrhea and intermittent abdominal pain, with chronic anemia, may be due to Crohn disease or celiac disease.

Hemoglobin levels as low as 5-6 g/dL are well tolerated in most patients, with transfusion not required. Parents, however, frequently note that patients become much more active following a transfusion or correction of anemia with iron therapy. A long-standing chronic anemia may result in growth failure.

Inquire carefully regarding any evidence of blood loss (eg, hemoptysis, hematochezia, melena, tarry stools, hematuria, menorrhagia). In endemic areas, a history of papulovesicular skin lesions on the feet may suggest a diagnosis of hookworm infestation. GI bleeding such as from intestinal vascular abnormalities is difficult to detect.[25]

Age is always an important consideration. Nutritional iron deficiency is seen in older infants and toddlers (aged 6 mo to 3 y), whereas iron deficiency due to blood loss occurs in menstruating girls. The deficiency can be surprisingly severe, but transfusion is indicated only in the rare circumstance of impending high-output cardiac failure.

The patient's sex must always be considered in hemolytic anemias. Severe G-6-PD deficiency may be seen as a chronic nonspherocytic anemia, usually in males.

As previously discussed, ethnicity is a factor in the hemoglobinopathies. Hemoglobin S syndromes (sickle cell disease) are usually seen in populations of central African origin. Hemoglobin C syndromes are seen in populations of western African origin. Hemoglobin D syndromes are usually seen in the population of northern India. Hemoglobin E syndromes are seen in populations of Southeast Asia. β-thalassemias are seen in Mediterranean, Middle Eastern, Indian, African, and Southeast Asian populations. Thalassemias involving the β chain are clinically silent in the first months of life and become apparent only after 6-9 months because of cessation of γ-chain production. α-Thalassemias are seen in African, Middle Eastern, and Asian populations.

Dietary history is important with regard to the amount and source of milk ingested by infants and toddlers. Strictly breastfed infants without iron supplement beyond age 8 months are at very high risk for iron deficiency anemia. Food aversions (eg, to leafy vegetables) can cause predisposition to folic acid deficiency. Folic acid deficiency also occurs in children fed exclusively with goat's milk. Certain diets (eg, vegan diet) can result in vitamin B12 deficiency if continued over several years.

Blood loss over an extended period results in iron deficiency. Chronic infection or inflammation, such as chronic pyelonephritis, bacterial endocarditis, osteomyelitis, or juvenile idiopathic arthritis, results in the anemia of chronic disease. Any inflammatory process, such as chronic renal failure or a chronic collagen vascular disease, also results in the anemia of chronic disease. Episodic pain in the chest, abdomen, or extremities may be due to a vaso-occlusive crisis of sickle cell disease.

Drugs with oxidant properties trigger hemolysis because of a G-6-PD deficiency, and hemolysis may become chronic if the drugs are continued for an extended period. Exposure to known marrow toxins, such as benzene or the antibiotic chloramphenicol, may result in aplastic anemia months after actual exposure.

Neonatal history may provide useful information regarding a possibly overlooked congenital process that manifested after birth. Exaggerated jaundice as a newborn may be a clue for HS or G-6-PD deficiency.

Family history is critical in any hereditary anemia. Anemia occurs in families with thalassemia syndromes. Gallstones, early cholecystectomy, and splenomegaly are common in families with HS.

Physical Examination

Vital signs, in contrast to those in acute anemia (such as anemia due to acute blood loss), are rarely abnormal in patients with chronic anemias, because adaptive mechanisms are well developed. Tachycardia on exertion is usually the only exception to this rule. An African girl aged 5 years with Hb of 1.9 g/dL was reported to have normal vital signs; the only abnormal findings were asthenia and a weight below the third centile. The patient had severe iron deficiency anemia plus sickle cell anemia.[26]

Growth curves may be affected by chronic anemia, usually in a symmetrical fashion, although head circumference is not affected.

Fanconi anemia is characterized by some or all of the following dysmorphic features: small stature, small head, absent thumbs, and café-au-lait spots.

Chronic hemolysis with extramedullary hematopoiesis, such as in β-thalassemia major or sickle cell anemia, may result in frontal bossing and prominent cheeks.

Pallor may be difficult to appreciate unless carefully sought. Pallor of the conjunctivae, nail beds, palm creases, or gums may be recognized. Parents and friends usually do not notice any difference, because the problem is chronic.

Scleral icterus is common in chronic hemolytic anemia. The icterus waxes and wanes.

Blue sclerae are well-documented findings of iron deficiency anemia, though there are other causes, such as osteogenesis imperfecta.

Petechiae and excessive bruises may indicate thrombocytopenia resulting from marrow aplasia or replacement by malignant cells. Less commonly, the same findings may reflect vasculitis resulting from infection or collagen vascular disease.

Papulovesicular lesions on the feet may suggest hookworm infestation.

Systolic murmur may be apparent and is usually loudest along the left sternal border, as is appropriate in any flow murmur.

Gallop rhythm, cardiomegaly, and hepatic enlargement may indicate early congestive heart failure.

Splenomegaly may indicate chronic hemolysis, as in HS, or elliptocytosis. It may also suggest hypersplenism due to many causes, such as portal hypertension or storage disease. Hypersplenism usually causes mild leukopenia and thrombocytopenia as well. Splenomegaly may also indicate leukemia, myelofibrosis, myeloproliferative disorder, or myelodysplastic syndrome.

Complications

Complications of pediatric chronic anemia include the following:

Approach Considerations

To evaluate anemia, obtain initial laboratory tests, including a complete blood count (CBC), a reticulocyte count, and a review of the peripheral smear. Imaging studies can play a role in the diagnosis of underlying disease, while bone marrow aspiration and biopsy can be used to identify the presence of tumor cells and determine cellular morphology.

Screening for anemia

American Academy of Pediatrics (AAP) guidelines recommend universal screening for anemia in children at about age 12 months, for a hemoglobin threshold of 110 g/L.[27]  However, this has been challenged in a study performed on well children in Toronto. That report found a correspondence between a hemoglobin level of 110 g/L and an undesirably low serum ferritin level of 4.6 μg/L. A hemoglobin threshold to 120 g/L, however, corresponded to a serum ferritin level of 17.9 μg/L, an apparently rational cutoff level.[28]

With ever-increasing evidence that during brain development, iron deficiency itself, not anemia, causes irreversible neurocognitive deficiency,[29] one needs to be certain that infants and toddlers not only do not have iron deficiency anemia but also do not have iron deficiency without anemia.

 

CBC Count

Note different normal ranges for different ages. Some laboratories provide only a uniform reference range for the entire pediatric age group and not for specific age groups. Interpret this carefully to avoid misdiagnosis. Hemoglobin and hematocrit levels can be used interchangeably, depending on professional preference and familiarity. Essentially, the hematocrit level is 3 times the hemoglobin value.

Red cell indices are quite informative, particularly mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW).

Note that reference ranges for these parameters also vary with age. Because of this, the author suggests using the MCV cut-off point of 70 plus age in years for patients aged 7 years or younger (eg, MCV < 72 is abnormal for a patient aged 2 y).

A high RDW (eg, ≥19-20) with microcytic picture is most often indicative of iron deficiency anemia in the pediatric population. The RDW is also very high in anemia with reticulocytosis, including sickle cell disease.

Macrocytosis suggests folate/vitamin B12 deficiency or hypothyroidism; however, nutritional deficiencies of these vitamins are rare. (The author encountered a 7-year-old boy with chronic abdominal pain and persistent MCV of between 90 and 100. This child turned out to have primary hypothyroidism; his newborn screening was allegedly normal.) Diamond-Blackfan anemia, aplastic anemia, and myelodysplastic syndrome often present with macrocytic anemia. Patients with sickle cell anemia who have been on hydroxyurea also show macrocytosis.

Note that in newborns, MCV is physiologically in the range of 96-108. Beyond the immediate newborn period, MCV exceeding 98 is very uncommon in children; if the volume exceeds 98, it usually indicates a serious hematologic problem, such as myelodysplastic syndrome, leukemia, aplastic anemia, Diamond-Blackfan anemia, or metabolic disorder.

In most, but not all, cases of HS, the MCHC exceeds the upper limit of the reference range.

Reticulocyte Count

Reticulocytes are immature, nonnucleated RBCs. An increase in the reticulocyte count (in particular, the absolute reticulocyte count) indicates active erythropoiesis.

The relative reticulocyte count is useful in determining whether anemia is caused by decreased production, increased destruction, or loss of RBCs. An elevated number of reticulocytes is (eventually) observed in individuals with anemia caused by hemolysis or blood loss; note that the absence of reticulocytosis may simply reflect a lag in the response to the acute onset of anemia. In some patients with autoimmune hemolytic anemia, the reticulocyte count may be depressed due to reticulocyte hemolysis as well.

The term reticulocyte count is often inaccurately used to refer to the percentage of reticulocytes, a value that must be interpreted in light of the degree of anemia. Thus, a finding of 2-3% reticulocytes (vs the reference value of approximately 1%) in a patient in whom the hemoglobin level is only one third to one half of reference range does not indicate a reticulocyte response.

Some clinicians prefer to use either the absolute number of reticulocytes/μL of blood or a reticulocyte percentage that is corrected for the degree of anemia. The corrected reticulocyte count equals (patient hematocrit)/(reference range hematocrit) multiplied by the percentage reticulocyte count.

The reticulocyte hemoglobin content (CHr) can be used to identify iron deficiency anemia. This is convenient, since many modern automated blood cell counters automatically measure this value. According to a study by Auerbach et al, a cutoff point of 30.7 pg for the reticulocyte hemoglobin equivalent (Ret-He; which is comparable but not identical to the CHr) resulted in identifying iron deficiency anemia with 68.2% sensitivity and 69.7% specificity.[30]

Peripheral Smear

Examination of the peripheral smear is particularly helpful in normocytic anemia. The red cell morphology itself is quite often diagnostic. The following are examples of abnormal cell morphology in a normocytic picture:

Normal RBC morphology does not exclude hemolysis.

Additional Laboratory Tests

Additional laboratory tests that may be indicated in the diagnosis and treatment of patients with acute anemia include the following:

A report by Abdullah et al convincingly argued against the appropriateness of screening tests using hemoglobin and serum ferritin levels of 110 g/L and 12 μg/L, respectively, as thresholds for detecting iron deficiency. In children aged 12-36 months with a hemoglobin level of 110g/L, the serum ferritin level may be as low as 2.4 μg, indicating iron deficiency. A linear relationship exists between serum ferritin level and blood hemoglobin concentration until—at a hemoglobin level of 121g/L and a ferritin concentration of 17.9 μg/L—ferritin increases no longer raise hemoglobin levels. The investigators therefore suggested that 121 g/L, rather than 110 g/L, serve as the hemoglobin threshold for iron deficiency.[28]

Radiography and Echocardiography

Chest radiography and echocardiography are indicated for suspected congestive heart failure.

Skull films and films of the hands and wrists may show expanded marrow space. Spine radiography may reveal a paraspinal (vertebral) pseudotumor due to marked expansion of the bone marrow (usually in thalassemia major).

Skeletal abnormalities may be seen in the following[31] :

Ultrasonography and CT Scanning

In cases of suspected hypersplenism, using ultrasonography or computed tomography (CT) scanning to detect a large spleen is not recommended. If a thorough physical examination does not detect a palpable spleen, hypersplenism is not a likely diagnosis.

Ultrasonography of the gallbladder for the presence of gallstones in patients with chronic hemolytic anemia may be valuable if the patient has recurrent abdominal pain. Abdominal pain due to gallstones in children is not always in the right upper quadrant. The author has received reports of left upper quadrant pain in children with gallstones that subsided after cholecystectomy.

Additional Studies

Other imaging studies are indicated to detect underlying pathology, including the following:

Exclude impending high-output congestive heart failure using electrocardiography (ECG).

Specimens from bone marrow aspiration and biopsy are often essential in helping to characterize overall cellularity, the presence or absence of malignant or tumor cells, the morphology and maturation of red cell precursors, and the presence or absence of stainable iron.

Bone marrow aspiration and biopsy can be used to rule out leukemia, aplastic anemia, tumor cells in the marrow (such as neuroblastoma), hemosiderosis, megaloblastosis, marrow dysplasia, and hemophagocytosis. It can also be employed in detection of the absence of one cell line due to pure red cell aplasia or parvovirus infection.

Approach Considerations

Chronic anemia merits prompt, if not immediate, attention.

Common sense should prevail in recognizing that, although anemia may be quite profound, the patient is usually well. In this circumstance, it is prudent not to follow the hemoglobin level too closely and thereby create unnecessary apprehension in the family. When physiologic adaptive mechanisms are in place, most children do well, and what is abnormal in others becomes normal in these children. At this point, the art of medicine takes precedence over the science of medicine.

Patients with chronic anemias rarely need inpatient care, even during the diagnostic process. Deal with complications on an ad hoc basis.

Oral Iron Supplementation

A report by Cohen and Powers recommended that in using oral iron supplements to treat adolescents with iron deficiency, iron absorption be maximized by administering supplementation only once per day, preferably in the morning, with avoidance of iron-absorption–inhibiting foods and drinks. Adolescents taking anemia-associated iron supplementation should continue with iron supplementation after the anemia has resolved, so that iron stores are replenished. Typically, supplements are required for up to 3 months to replace iron stores. In “otherwise healthy adolescents, a threshold of ferritin of 20 ng/mL should be achieved before discontinuing iron,” while adolescents with persistent risk factors may need ongoing, intermittent supplementation.[32]

Similarly, updated clinical practice guidelines on the management of iron deficiency anemia, published in 2024 by the American Gastroenterological Association (AGA), state that oral iron supplementation should be administered once daily at most, while some patients may better tolerate dosing every other day, “with similar or equal rates of iron absorption as daily dosing.” The guidelines also state that absorption of oral iron supplements can be improved by adding vitamin C to supplementation.[33]

Intravenous (IV) Iron

The aforementioned report by Cohen and Powers states that adolescents who, despite oral iron supplementation, have persistent iron deficiency; those with severe and/or symptomatic iron deficiency anemia; and those with “chronic inflammatory conditions characterized by decreased gastrointestinal iron absorption,” should be considered for IV iron.[32]

The aforementioned AGA guidelines on the management of iron deficiency anemia state that it is preferable when administering IV iron supplementation to use those formulations that can replenish iron deficits with 1-2 infusions rather than those that need more than two infusions.[33]

Transfusion

Exclusion of impending high-output cardiac failure is the most important issue. High-output failure is the only reason that blood transfusion is necessary.

RBC transfusions must be performed cautiously; rapid expansion of intravascular volume may cause congestive heart failure in a well-compensated patient. Two or more small aliquots of RBCs may need to be administered, with a few hours of reequilibration between transfusions.

Rapid volume expansion with normal saline, usually performed in the emergency department in chronically anemic children, also may cause congestive heart failure. One needs to assess the benefits and risks of volume expansion in this situation before one decides to give a normal saline bolus.

Elective surgery can usually be performed without preoperative transfusion as long as blood is available.

For patients who require long-term transfusional support, identification of a limited number of dedicated blood donors is desirable. Donors are selected on the basis of detailed antigenic crossmatching with the patient in hopes of avoiding development of immune-mediated hemolysis. Obtain serum ferritin values every 6-10 units of transfusion. If ferritin exceeds 1000 µg/L, start deferasirox or deferoxamine therapy.

According to recommendations by the Pediatric Critical Care Transfusion and Anemia eXpertise Initiative (TAXI) regarding transfusion indications for patients hospitalized in pediatric intensive care units (PICUs), RBC transfusion is not recommended in hemodynamically stable children (≥36 weeks gestational age and less than age 18 years) with Hb of 7g/dL or above. This recommendation includes postsurgical (excluding post–cardiac surgery) patients as long as there is no significant hemorrhage. Those whose Hb is below 5 g/dL are to receive transfusion, while patients whose Hb is between 5 and 7 should be individually considered for transfusion indications. Post-transfusion Hb levels should be aimed at above 7 g/dL but below 9.5 g/dL.[34] There are a number of study findings in the pediatric and adult literature that show increased morbidity and mortality associated with blood transfusions in patients hospitalized in ICU settings.

Splenectomy

Splenectomy is often indicated in patients with HS, but not necessarily during the pediatric age. Delay splenectomy until patients are aged 8-9 years, by which time immunity to encapsulated bacteria is well established. Typically, this is also before hemolysis sufficient to result in bilirubin gallstones has occurred. However, in some patients, repetitive splenic sequestration develops, necessitating earlier splenectomy.

Intrafamilial variation is common in terms of anemia's severity; thus, a history of childhood splenectomy in a parent does not necessarily indicate a need for splenectomy in the affected child.

Vaccination against encapsulated organisms is a must prior to splenectomy. Also, there is an increased risk of thromboembolic events associated with splenectomy, and a careful, individualized benefit-risk ratio should be evaluated before deciding whether to perform the procedure.

Prevention of Anemia

Dietary iron deficiency anemia can be prevented by starting supplemental iron when infants are weaned off breast milk or regular formula at age 6-8 months; 1-2 mg/kg/d of elemental iron is usually sufficient to prevent iron deficiency anemia. This should be continued until the child more or less eats regular table foods as the main source of calories. Treatment of iron deficiency anemia needs a higher dose of iron, usually 6 mg/kg/d of elemental iron, for at least 3 months.

Infants of vegan mothers who exclusively breastfeed may develop megaloblastic anemia and neurologic signs due to B12 deficiency. These infants should be given B12 supplementation.

There are concerns regarding the potential deleterious developmental effects of excess iron exposure in early childhood. In a randomized evaluation by Lozoff et al of low-iron versus iron-supplemented formulas in Chile, a 10-year follow-up suggested the presence of subtle neurocognitive deficits specifically in those infants with higher hemoglobin levels at the time of randomization. A possible explanation offered by the investigators is that adverse impacts on neurodevelopmental outcome may occur in iron-sufficient infants who receive supplemental iron, but there have not been subsequent confirmatory studies.[35]

Consultations

Many chronic anemias can be diagnosed and managed by generalists. However, when subtle distinctions in morphology or interpretation of laboratory data relative to hemolytic anemia are important, a pediatric hematologist is usually needed. Certainly, when bone marrow aspiration and biopsy are contemplated, the experience of a pediatric hematologist is essential.

Unless readily explained by an increased reticulocyte count or another physiologic condition, macrocytosis usually warrants consultation with a hematologist.

A number of children with hypochromic anemia outside the dietary iron deficiency age are ultimately found to have chronic GI bleeding. It is essential in this situation to work closely with a pediatric gastroenterologist.

Although rare, congenital sideroblastic anemia may present as hypochromic, microcytic anemia in infants. Ringed sideroblasts, ie, erythroid precursors with pathologic, perinuclear iron-loaded mitochondria, occur in bone marrow, characterizing this disorder of abnormal erythropoiesis. Bone marrow examination is necessary to establish the diagnosis.[36]  

Long-Term Monitoring

Monitor growth and development, nutritional status, degree of splenomegaly, formation of gallstones, onset of puberty, endocrine status, and any potential complications related to underlying disorders.

Medication Summary

Medications are dictated by underlying disorders.

Since the start of the 21st century, safer IV forms of iron have become available, with an increasing number of patients with severe iron deficiency having been treated with this form of iron preparation. The IV form can eliminate concerns regarding nonadherence and gastrointestinal adverse effects of oral preparations. Currently, there are several commercially available preparations in the United States and/or Europe, including low–molecular-weight dextran, iron sucrose, ferric gluconate, ferumoxytol, ferric carboxymaltose, and iron isomaltoside.

Due to a need for a high rate of RBC production, patients with chronic hemolytic anemia caused by intrinsic RBC abnormalities such as hemoglobinopathies, unstable hemoglobins, and red cell membrane or red cell enzyme abnormalities may need daily folic acid supplementation.

Patients who receive routine blood transfusions develop iron overload and thus require iron chelation. Available oral preparations include deferasirox and deferiprone; classic deferoxamine, which needs to be given parenterally, is also available.

Nutritional anemia can be treated with supplements of deficient factors (folic acid, vitamin B12, pyridoxine, copper, etc.)

Recombinant erythropoietin has been useful in managing anemia related to chronic renal failure, rheumatoid arthritis, AIDS, and DMT1 protein mutation.[37] Hemoglobin levels and general feelings of well-being have been much improved in patients since this agent became commercially available.

Cyanocobalamin (Athlete, Calomist, Cobalamin)

Clinical Context:  This agent is used to treat megaloblastic anemia resulting from vitamin B12 deficiency. Deoxyadenosylcobalamin and hydroxocobalamin are active forms of vitamin B12 in humans. Vitamin B12 is synthesized by microbes but not by humans or plants. Deficiency may result from intrinsic factor deficiency (pernicious anemia), partial or total gastrectomy, or diseases of the distal ileum. Deficiency initially and typically manifests as macrocytic anemia, although neurologic symptoms may be present. They can also cause confusion or delirium in elderly patients.

Vitamin B12 is essential for normal erythropoiesis and is required for healthy neuronal function and normal function of rapidly growing cells.

Class Summary

These agents are essential for normal metabolism and DNA synthesis.

Ferrous sulfate (Feosol, Fer-In-Sol, Feratab)

Clinical Context:  This is the mainstay treatment for patients with iron deficiency anemia. It is used as a building block for hemoglobin synthesis in treating anemia. It allows transportation of oxygen via hemoglobin and is necessary for oxidative processes of living tissue. Treatment should continue for about 2 months after correction of anemia and the etiologic cause in order to replenish the body stores of iron. Ferrous sulfate is the most common and inexpensive form of iron used. Tablets contain 50-60 mg of iron salt. Other ferrous salts are used and may cause less intestinal discomfort because they contain smaller doses of iron (25-50 mg). Oral solutions of ferrous iron salts are available for use in pediatric populations.

Dietary iron deficiency anemia can be prevented by starting supplemental iron when infants are weaned off breast milk or regular formula at age 6-8 months.

The authors recommend 6 mg/kg/d of elemental iron for 6 months for infants and children with severe iron deficiency anemia. Please note the dose is based on the weight of elemental iron, not of iron salts.

Class Summary

These agents are useful for the treatment of iron deficiency anemia.

Epoetin alfa (Epoetin alfa-epbx, Epogen, Eprex)

Clinical Context:  This is a purified glycoprotein produced from mammalian cells and modified with the gene coding for human erythropoietin. The amino acid sequence is identical to that of endogenous erythropoietin. Its biologic activity mimics human urinary erythropoietin, which stimulates division and differentiation of committed erythroid progenitor cells and induces the release of reticulocytes from bone marrow into the bloodstream.

Class Summary

These agents are used to manage anemia related to chronic renal failure, rheumatoid arthritis, and AIDS.

Deferoxamine (Desferal)

Clinical Context:  Deferoxamine is freely soluble in water. Approximately 8 mg of iron is bound by 100 mg of deferoxamine. Deferoxamine is excreted in urine and bile and discolors the urine red. It readily chelates iron from ferritin and hemosiderin but not from transferrin. It is most effective when provided to the circulation continuously by means of infusion. Deferoxamine may be administered by IM injection, slow infusion, SC bolus, or continuous infusion. It does not effectively chelate other trace metals of nutritional importance.

Deferasirox (Exjade, Jadenu, Jadenu Sprinkle)

Clinical Context:  Deferasirox is available as a tablet for oral suspension. It is an oral iron-chelating agent demonstrated to reduce liver iron concentration in adults and children who receive repeated RBC transfusions. Deferasirox binds iron with high affinity in a 2:1 ratio. It is approved for treatment of chronic iron overload due to multiple blood transfusions. Treatment initiation is recommended when evidence of chronic iron overload (ie, transfusion of about 100 mL/kg packed RBCs [about 20 U for 40-kg person] and serum ferritin level consistently >1000 µg/L) is noted.

Deferiprone (Ferriprox)

Clinical Context:  1,2 dimethyl-3-hydroxypyridine-4-one is a member of a family of hydroxypyridine-4-one (HPO) chelators that requires 3 molecules to fully bind iron (III), each molecule providing 2 coordination sites (bidentate chelation). Its half-life is approximately 2 hours. The inactive metabolite is predominantly excreted in urine. Deferiprone is indicated for transfusional iron overload caused by thalassemia syndromes when current chelation therapy is inadequate.

Class Summary

Iron overload (usually from multiple transfusions) may require chelation therapy, which usually begins when the ferritin level is greater than 1000 ng/mL.

Author

Susumu Inoue, MD, Professor of Pediatrics and Human Development, Michigan State University College of Human Medicine; Clinical Professor of Pediatrics, Wayne State University School of Medicine; Director of Pediatric Hematology/Oncology, Hurley Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

John T Truman, MD, MPH, Professor Emeritus of Clinical Pediatrics, Columbia University College of Physicians and Surgeons

Disclosure: Nothing to disclose.

Margaret T Lee, MD, Associate Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology/SCT, Children's Hospital of New York, Columbia University College of Physicians and Surgeons

Disclosure: Nothing to disclose.

Specialty Editors

Mary L Windle, PharmD, Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Lawrence C Wolfe, MD, Associate Chief for Hematology and Safety, Division of Pediatric Hematology-Oncology, Cohen Children's Medical Center

Disclosure: Nothing to disclose.

Additional Contributors

J Martin Johnston, MD, Associate Professor of Pediatrics, Mercer University School of Medicine; Director of Hematology/Oncology, The Children's Hospital at Memorial University Medical Center; Consulting Oncologist/Hematologist, St Damien's Pediatric Hospital

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD, Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Disclosure: Nothing to disclose.

References

  1. Aljomah G, Baker SS, Schmidt K, et al. Anemia in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2018 Sep. 67 (3):351-5. [View Abstract]
  2. Vu C, Bush A, Choi S, et al. Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias. Am J Hematol. 2021 Aug 1. 96 (8):901-13. [View Abstract]
  3. Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood. 2012 Nov 8. 120(19):3891-7. [View Abstract]
  4. Baker C, Grant AM, George MG, Grosse SD, Adamkiewicz TV. Contribution of Sickle Cell Disease to the Pediatric Stroke Burden Among Hospital Discharges of African-Americans-United States, 1997-2012. Pediatr Blood Cancer. 2015 Dec. 62 (12):2076-81. [View Abstract]
  5. Skeppner G, Kreuger A, Elinder G. Transient erythroblastopenia of childhood: prospective study of 10 patients with special reference to viral infections. J Pediatr Hematol Oncol. 2002 May. 24(4):294-8. [View Abstract]
  6. Penchansky L, Jordan JA. Transient erythroblastopenia of childhood associated with human herpesvirus type 6, variant B. Am J Clin Pathol. 1997 Aug. 108(2):127-32. [View Abstract]
  7. Prassouli A, Papadakis V, Tsakris A, Stefanaki K, Garoufi A, Haidas S. Classic transient erythroblastopenia of childhood with human parvovirus B19 genome detection in the blood and bone marrow. J Pediatr Hematol Oncol. 2005 Jun. 27(6):333-6. [View Abstract]
  8. Jacobson AE, Kahwash SB, Chawla A. Refractory cytopenias secondary to copper deficiency in children receiving exclusive jejunal nutrition. Pediatr Blood Cancer. 2017 Nov. 64 (11):[View Abstract]
  9. Vale M, Prochazka J, Sedlacek R. Towards a Cure for Diamond-Blackfan Anemia: Views on Gene Therapy. Cells. 2024 May 27. 13 (11):[View Abstract]
  10. Takeuchi I, Tanase-Nakao K, Ogawa A, et al. Congenital anaemia associated with loss-of-function variants in DNA polymerase epsilon 1. J Med Genet. 2024 Feb 21. 61 (3):239-43. [View Abstract]
  11. Zhou T, Zeng C, Xi Q, Yang Z. SNX10 gene mutation in infantile malignant osteopetrosis: A case report and literature review. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Jan 28. 46 (1):108-12. [View Abstract]
  12. Mullikin D, Grimes AB. 50 Years Ago in The Journal of Pediatrics: Thiamine-Responsive Megaloblastic Anemia. J Pediatr. 2019 Apr. 207:53. [View Abstract]
  13. Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, et al. Congenital Dyserythropoietic Anemia Type I. GeneReviews. Updated 2021 Jul 29. [View Abstract]
  14. Choquet P, Levrat V, Pondarre C, Vianney C, Guffon N. [Imerslund-Gräsbeck syndrome]. Arch Pediatr. 2009 Dec. 16 (12):1559-61. [View Abstract]
  15. Wild KT, Goldstein AC, Muraresku C, Ganetzky RD. Broadening the phenotypic spectrum of Pearson syndrome: Five new cases and a review of the literature. Am J Med Genet A. 2020 Feb. 182 (2):365-73. [View Abstract]
  16. Iolascon A, De Falco L, Beaumont C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica. 2009 Mar. 94 (3):395-408. [View Abstract]
  17. Iolascon A, Camaschella C, Pospisilova D, Piscopo C, Tchernia G, Beaumont C. Natural history of recessive inheritance of DMT1 mutations. J Pediatr. 2008 Jan. 152(1):136-9. [View Abstract]
  18. [Guideline] Faughnan ME, Mager JJ, Hetts SW, Palda VA, Ratjen F. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2021 Jul. 174 (7):1035-6. [View Abstract]
  19. Restivo GA, Scalzo S, Di Palermo A. Mechanical Hemolytic Anemia Associated With Mitral Valve Repair: A Case Report With Literature Review. J Pediatr Hematol Oncol. 2023 Nov 1. 45 (8):e993-5. [View Abstract]
  20. Sion JL, Flores ALH, Cardoso RA, Garanito MP. Human adenovirus associated with severe cold agglutinin syndrome: a rare complication in Pediatrics. Rev Paul Pediatr. 2023. 42:e2022174. [View Abstract]
  21. Stevens GA, Paciorek CJ, Flores-Urrutia MC, et al. National, regional, and global estimates of anaemia by severity in women and children for 2000-19: a pooled analysis of population-representative data. Lancet Glob Health. 2022 May. 10 (5):e627-39. [View Abstract]
  22. Henderson S, Timbs A, McCarthy J, Gallienne A, Van Mourik M, Masters G. Incidence of haemoglobinopathies in various populations - the impact of immigration. Clin Biochem. 2009 Dec. 42(18):1745-56. [View Abstract]
  23. Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med. 2012 Sep. 2(9):a011692. [View Abstract]
  24. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010 Jun 3. 115(22):4331-6. [View Abstract]
  25. Kim SH, Cho YH, Kim HY. Vascular malformations of the small intestine manifesting as chronic anemia: Two pediatric cases managed by single-site umbilical laparoscopic surgery. Int J Surg Case Rep. 2017. 31:233-6. [View Abstract]
  26. Parodi E, Riboldi L, Ramenghi U. Hemoglobin life-threatening value (1.9 g/dl) in good general condition: a pediatric case-report. Ital J Pediatr. 2021 Oct 7. 47 (1):200. [View Abstract]
  27. Baker RD, Greer FR. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics. 2010 Nov. 126(5):1040-50. [View Abstract]
  28. Abdullah K, Birken CS, Maguire JL, et al. Re-Evaluation of Serum Ferritin Cut-Off Values for the Diagnosis of Iron Deficiency in Children Aged 12-36 Months. J Pediatr. 2017 Sep. 188:287-90. [View Abstract]
  29. Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T, Pino P. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. Pediatrics. 2003 Oct. 112 (4):846-54. [View Abstract]
  30. Auerbach M, Staffa SJ, Brugnara C. Using Reticulocyte Hemoglobin Equivalent as a Marker for Iron Deficiency and Responsiveness to Iron Therapy. Mayo Clin Proc. 2021 Jun. 96 (6):1510-9. [View Abstract]
  31. Favareto F, Caprino D, Micalizzi C, Rosanda C, Boeri E, Mori PG. New clinical aspects of Pearson's syndrome. Report of three cases. Haematologica. 1989 Nov-Dec. 74 (6):591-4. [View Abstract]
  32. Cohen CT, Powers JM. Nutritional Strategies for Managing Iron Deficiency in Adolescents: Approaches to a Challenging but Common Problem. Adv Nutr. 2024 May. 15 (5):100215. [View Abstract]
  33. [Guideline] DeLoughery TG, Jackson CS, Ko CW, Rockey DC. AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review. Clin Gastroenterol Hepatol. 2024 Aug. 22 (8):1575-83. [View Abstract]
  34. [Guideline] Doctor A, Cholette JM, Remy KE, et al. Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018 Sep. 19 (9S Suppl 1):S98-S113. [View Abstract]
  35. Lozoff B, Castillo M, Clark KM, Smith JB. Iron-fortified vs low-iron infant formula: developmental outcome at 10 years. Arch Pediatr Adolesc Med. 2012 Mar. 166(3):208-15. [View Abstract]
  36. Wiseman DH, May A, Jolles S, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood. 2013 Jul 4. 122 (1):112-23. [View Abstract]
  37. Iolascon A, De Falco L. Mutations in the gene encoding DMT1: clinical presentation and treatment. Semin Hematol. 2009 Oct. 46 (4):358-70. [View Abstract]

Blood smear from a Black male with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency that resulted in acute hemolysis. Note blister (helmet or bite) cells and very dense spherocytic cells. The blood smear is virtually pathognomic of this disorder.

Blood smear of hereditary spherocytosis (HS). Note many spherocytic cells. Not all patients with HS are anemic.

Blood smear of hemoglobin C trait. Note numerous target cells. Target cells are a characteristic of this hemoglobinopathy. The trait patient has no anemia. Target cells are also seen in patients with iron deficiency anemia, thalassemia, sickle cell disease, and liver disease.

Blood smear of a patient with homozygous sickle cell disease. Note several sickle cells, a nucleated RBC, and a red cell with Howell-Jolly body (indicated by an arrow), evidence of functional asplenia.

A blood smear showing a few schistocytes. This patient had Kaposi-type hemangioendothelioma with periodic microangiopathic hemolysis and disseminated coagulopathy (Kasabach-Merritt phenomenon).

A blood smear of a patient with beta-thalassemia trait. Note red cells pointed by arrows. Multiple bluish dots in the cells are called basophilic stipplings and consist of aggregated ribosomes. They are often present in immature red cells such as reticulocytes.

Blood smear from a Black male with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency that resulted in acute hemolysis. Note blister (helmet or bite) cells and very dense spherocytic cells. The blood smear is virtually pathognomic of this disorder.

Blood smear of hereditary spherocytosis (HS). Note many spherocytic cells. Not all patients with HS are anemic.

Blood smear of hemoglobin C trait. Note numerous target cells. Target cells are a characteristic of this hemoglobinopathy. The trait patient has no anemia. Target cells are also seen in patients with iron deficiency anemia, thalassemia, sickle cell disease, and liver disease.

Blood smear of a patient with homozygous sickle cell disease. Note several sickle cells, a nucleated RBC, and a red cell with Howell-Jolly body (indicated by an arrow), evidence of functional asplenia.

A blood smear showing a few schistocytes. This patient had Kaposi-type hemangioendothelioma with periodic microangiopathic hemolysis and disseminated coagulopathy (Kasabach-Merritt phenomenon).

A blood smear of a patient with beta-thalassemia trait. Note red cells pointed by arrows. Multiple bluish dots in the cells are called basophilic stipplings and consist of aggregated ribosomes. They are often present in immature red cells such as reticulocytes.